Dr. John Cush RheumNow
3 years 1 month ago
ICYMI: Carpal Tunnel - Steroid injection vs. Night Splinting
A trial conducted by the UK National Health Service, studied interventions in patients with CTS and found no advantage to either CTS CSI or NS as the initial treatment.
https://t.co/b8yZSKRK2X https://t.co/zOYaYOtuJd
Dr. John Cush RheumNow
3 years 1 month ago
Pain is the leading cause of disability worldwide. Chronic pain affects 33-50% of the population. High impact chronic pain is seen in 4.8% of US adult population. Chronic pain accounts for 22-50% of GP consultations. More from BMJ.. https://t.co/IRVpJZNS0L https://t.co/YVIM38aWWK
Dr. John Cush RheumNow
3 years 1 month ago
Full read review of "Treatments for Lupus Nephritis" from Isenberg et al - discussing:
- Pathogenesis, outcomes
- Conventional Rx
- B cell targeting: BEL, RTX, Obintuzumab, Atacicept & more
- Sequential Rx: Synviose, BEAT, BLISS-Believe
- JAKi & more https://t.co/X0xn9FeL0j https://t.co/Fiyf5Drh93
A phase 3 trial assessed a selective Janus kinase 1/2-inhibitor, baricitinib, in patients with juvenile idiopathic arthritis (JIA), demonstrating it's efficacy and safety compared to placebo.
Cerebrovascular ischemic events (CIE) can be one of the most severe complications of giant cell arteritis (GCA), but is seen in 4-5% of GCA patients according to a recent French University Hospital.
Dr. John Cush RheumNow
3 years 1 month ago
Bringing pivotal clinical trials to you: announcing RheumNow’s Poster Hall, featuring previously presented, sponsor-generated clinical trial posters designed to educate and inform.
https://t.co/CeLTCbB2nO https://t.co/qYXt8gCHjd
Dr. John Cush RheumNow
3 years 1 month ago
NIH MOST study 2093 OA pts w/ Knee Xrays/CT/Pain scores q8 mos x2 yrs. IA mineralization seen in 10% knees & assoc w/ a 2 fold higher risk of freq knee pain & OR 1.86 of freq intermit/constant pain. IA mineralz. meniscus or Jt capsule=higher odds of pain https://t.co/CacJ40DVyL https://t.co/Zhwv98d6Pe
Dr. John Cush RheumNow
3 years 1 month ago
Since the end of COVID, how often do you see Pharma Sales Reps (PSRs)?
Dr. John Cush RheumNow
3 years 1 month ago
Scleroderma – Thick and Thin
This week focuses on parodoxical psoriasis, scleroderma outcomes and subsets, and alopecia areata therapy.
https://t.co/IF5c8MF1zk https://t.co/zhwR4SofHt
Dr. John Cush RheumNow
3 years 1 month ago
In Memoriam: Dr. K. Frank Austen (1928-2023)
Rheumatology mourns the loss of a historic leader in the field, Dr. K. Frank Austen, who died at his home in Maine on June 23, 2023, at the age of 95.
https://t.co/mtRQ8D5bWt https://t.co/fAQ9ebK95R
Dr. John Cush RheumNow
3 years 1 month ago
Scary Outcomes with Systemic Sclerosis Sine Scleroderma
The hallmark of SSc is scleroderma, but less than 10% of SSc patients have ssSSc. A EUSTAR database review compared the manifestations and outcomes of ssSSC to lcSSc and dcSSc.
https://t.co/WwwmDxt5DL https://t.co/iXepaWvoCY
Dr. John Cush RheumNow
3 years 1 month ago
Opioids Ineffective in Acute Lower Back and Neck Pain
A randomised controlled trial including 347 participants with lower back or neck pain found there was no benefit of taking opioid pain relievers compared to placebo.
https://t.co/96mETyhKyL https://t.co/48ojNCnoZW
Dr. John Cush RheumNow
3 years 1 month ago
Remembering Dr. Naomi F. Rothfield - As one of UConn School of Medicine’s first women faculty, legendary internationally-renowned rheumatologist Dr. had a nearly 50 year career at UConn Health retiring in 2016. She passed away on Sunday, July 2. https://t.co/jUESbCySRR https://t.co/50inpx7xRW
Dr. John Cush RheumNow
3 years 1 month ago
Full read review of clinical trials in CTD-ILD, specifically looking at:
- Frequency of ILD in RA, SLE, SSc, Sjogr, PM/DM & Rx outcomes
- Results w/ RTX, MMF, CYC, IL-6i, nintedinib, pirfenidone, Stem cell transplant
https://t.co/gUOV3IWt4P https://t.co/WM1HvTmNCq
A safety analysis of six phase III SELECT trials showed that higher-risk rheumatoid arthritis (RA) patients had an increased risk of MACE, malignancy (excluding NMSC) and venous thromboembolic events (VTE) regardless of being treated with either upadacitinib (UPA) or adalimumab (ADA).
